Aquinox Pharmaceuticals: Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Files An 8-K Costs Associated with Exit or Disposal Activities

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Files An 8-K Costs Associated with Exit or Disposal Activities Item 2.05. Costs Associated with Exit or Disposal Activities. On July3, 2018, the Compensation Committee of the Board of Directors of Aquinox Pharmaceuticals, Inc. (the “Company”) approved a restructuring plan to reduce operating costs and better align the Company’s workforce with the needs of its business following the June27, 2018 announcement that its Phase 3 LEADERSHIP 301 clinical trial evaluating once-daily, oral rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) failed to meet its primary endpoint. The Company has halted all further development activities with rosiptor.